中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
18期
38-39
,共2页
地榆升白片%甘露聚糖肽%原发性白细胞减少症%细胞免疫功能
地榆升白片%甘露聚糖肽%原髮性白細胞減少癥%細胞免疫功能
지유승백편%감로취당태%원발성백세포감소증%세포면역공능
Diyushengbai tablet%Mannatide%Primary leucopenia%Cellular immune function
目的 探讨分析地榆升白片联合甘露聚糖肽治疗原发性白细胞减少症的临床疗效及对患者T淋巴细胞亚群的影响.方法 选择2010年5月至2014年5月间许昌市中心医院收治的120例原发性白细胞减少症患者为研究对象,采用随机数字表法均分为观察组和对照组,前者予地榆升白片联合甘露聚糖肽治疗;后者仅予甘露聚糖肽治疗.观察两组疗效,统计红细胞C3b受体花环率(E-C3 b-RR)、红细胞免疫复合物花环率(E-IC-R)、CD3+、CD4+、CD8+、CD4 +/CD8+变化情况.结果 观察组治疗总有效率(88.3％,53/60)显著高于对照组(70.0％,42/60),差异具有统计学意义(P＜0.05);治疗前两组E-C3 b-RR、E-IC-R、CD3+、CD4+、CD8+、CD4+/CD8+差异均未见统计学意义,治疗后观察组E-C3 b-RR、CD4+、CD4 +/CD8+显著高于对照组,而E-IC-R、CD8+显著低于对照组,差异均有统计学意义(P＜0.05).结论 地榆升白片联合甘露聚糖肽治疗原发性白细胞减少症患者,疗效显著,机制可能与调节细胞免疫功能有关.
目的 探討分析地榆升白片聯閤甘露聚糖肽治療原髮性白細胞減少癥的臨床療效及對患者T淋巴細胞亞群的影響.方法 選擇2010年5月至2014年5月間許昌市中心醫院收治的120例原髮性白細胞減少癥患者為研究對象,採用隨機數字錶法均分為觀察組和對照組,前者予地榆升白片聯閤甘露聚糖肽治療;後者僅予甘露聚糖肽治療.觀察兩組療效,統計紅細胞C3b受體花環率(E-C3 b-RR)、紅細胞免疫複閤物花環率(E-IC-R)、CD3+、CD4+、CD8+、CD4 +/CD8+變化情況.結果 觀察組治療總有效率(88.3％,53/60)顯著高于對照組(70.0％,42/60),差異具有統計學意義(P＜0.05);治療前兩組E-C3 b-RR、E-IC-R、CD3+、CD4+、CD8+、CD4+/CD8+差異均未見統計學意義,治療後觀察組E-C3 b-RR、CD4+、CD4 +/CD8+顯著高于對照組,而E-IC-R、CD8+顯著低于對照組,差異均有統計學意義(P＜0.05).結論 地榆升白片聯閤甘露聚糖肽治療原髮性白細胞減少癥患者,療效顯著,機製可能與調節細胞免疫功能有關.
목적 탐토분석지유승백편연합감로취당태치료원발성백세포감소증적림상료효급대환자T림파세포아군적영향.방법 선택2010년5월지2014년5월간허창시중심의원수치적120례원발성백세포감소증환자위연구대상,채용수궤수자표법균분위관찰조화대조조,전자여지유승백편연합감로취당태치료;후자부여감로취당태치료.관찰량조료효,통계홍세포C3b수체화배솔(E-C3 b-RR)、홍세포면역복합물화배솔(E-IC-R)、CD3+、CD4+、CD8+、CD4 +/CD8+변화정황.결과 관찰조치료총유효솔(88.3％,53/60)현저고우대조조(70.0％,42/60),차이구유통계학의의(P＜0.05);치료전량조E-C3 b-RR、E-IC-R、CD3+、CD4+、CD8+、CD4+/CD8+차이균미견통계학의의,치료후관찰조E-C3 b-RR、CD4+、CD4 +/CD8+현저고우대조조,이E-IC-R、CD8+현저저우대조조,차이균유통계학의의(P＜0.05).결론 지유승백편연합감로취당태치료원발성백세포감소증환자,료효현저,궤제가능여조절세포면역공능유관.
Objective To investigate the clinical curative effect of diyushengbai tablet combined with mannatide on T lymphocyte subsets of patients with primary leucopenia.Methods One hundred and twenty patients with primary leucopenia from May 2010 to May 2014 in Xuchang Central Hospital were chosen as the research objects,and were divided into observation group and control group with random number table method.The patients in observation group were given diyushengbai tablet combined with mannatide,and the patients in control group were given mannatide merely.The red blood cell C3b receptor (E-C3b-RR) and erythrocyte immune complex lei rate (E-IC-R),CD3 +,CD4 +,CD8 +,CD4 +/CD8 + changes were observed and recorded.Results The total effective rate of observation group (88.3％,53/60,53/60) was significantly higher than that of the control group (70.0％,42/60),and the difference was significant (P ＜ 0.05);E-C3 b-RR,E-IC-R,CD3 +,CD4 +,CD8 +,CD4 + / CD8 + of the two groups before treatment had no significant difference,and after treatment,the E-C3b RR,CD4 +,CD4 +/CD8 + were significantly higher and E-IC-R,CD8 + significantly lower in observation group;all the differences above had statistical significance (P ＜ 0.05).Conclusions Diyushengbai tablet combined with mannatide is effective on patients with primary leucopenia,and the mechanism may be related to regulate cellular immune function.
